The carbapenem antibiotics (imipenem, meropenem and doripenem) are considered the agents of choice for A. baumannii infections. The presence of resistance to these agents constrains therapeutic ...

Scientists at the Ineos Oxford Institute (IOI) have found a new potential combination therapy to combat antimicrobial resistance (AMR) by targeting two key bacterial enzymes involved in resistance.

Carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa are a global threat to antimicrobial resistance and may be causative pathogens in cUTI. Cefepime-taniborbactam ...

A new bacterial threat, the carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP), is rapidly spreading in clinical environments in China, posing a significant public health challenge.

Enterobacteria such as Escherichia coli or Klebsiella pneumoniae are dreaded hospital germs that can cause serious intestinal and urinary tract infections. The risk of infection with these pathogens ...

New research has identified positive steps toward a better understanding of antimicrobial resistance (AMR), specifically in hospital-acquired pneumonia (HAP). Antimicrobial, or antibiotic resistance, ...

Carbapenem-resistant Enterobacterales species and multidrug-resistant Pseudomonas aeruginosa are global health threats. Cefepime–taniborbactam is an investigational β-lactam and β-lactamase inhibitor ...

Antibiotic resistance has become a growing problem. When bacteria become antibiotic-resistant, treatment options become limited. Carbapenems are effective antibiotics that work on a wide range of ...